Role of Genetic Polymorphisms in the Development of Nonalcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH)

被引：0
|
作者：
Bril, Fernando [1 ,2 ]
Kawaguchi-Suzuki, Marina [1 ]
Frye, Reginald [1 ]
Sanchez, Paola Portillo [1 ,2 ]
Maximos, Maryann [1 ]
Lai, Song [3 ]
Hardies, Jean [4 ]
Tio, Fermin [4 ]
Cusi, Kenneth [1 ,2 ]
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Malcom Randall VA Med Ctr, Gainesville, FL USA
[3] Univ Florida, CTSI Human Imaging Core McKnight Brain Inst, Gainesville, FL USA
[4] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
799
引用
收藏
页码：585A / 585A
页数：1
相关论文
共 50 条
  • [41] High Risk of Mortality and Disease Progression Associated with Diabetes Mellitus (DM) and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) in Medicare Patients
    Loomba, Rohit
    Fraysse, Jeremy
    Li, Suying
    Ozbay, A. Burak
    DIABETES, 2019, 68
  • [42] The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Chow, Monica D.
    Lee, Yi-Horng
    Guo, Grace L.
    MOLECULAR ASPECTS OF MEDICINE, 2017, 56 : 34 - 44
  • [43] Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    不详
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (05)
  • [44] FIBROTIC NASH INDEX ( FNI) IN DIABETICS WITH NONALCOHOLIC FATTY LIVER DISEASE ( NAFLD)
    Golabi, Pegah
    Estep, James M.
    Felix, Sean
    Stepanova, Maria
    Owrangi, Soroor
    Lam, Brian P.
    Meneses, Maria Joao
    Racila, Andrei
    Castera, Laurent
    Macedo, Maria Paula
    Younossi, Zobair M.
    HEPATOLOGY, 2023, 78 : S799 - S799
  • [45] THE DIPEPTIDYL PEPTIDASE 4 INHIBITOR LINAGLIPTIN IS AN EFFECTIVE THERAPEUTIC FOR METABOLIC LIVER DISEASE IN SEVERAL RODENT MODELS OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH)
    Klein, Thomas
    Mark, Michael
    Schuppan, Detlef
    HEPATOLOGY, 2011, 54 : 369A - 369A
  • [46] Concomitance of nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) is associated with the histological severity in Hepatitis B virus-infected liver
    Aizawa, Nobuhiro
    Enomoto, Hirayuki
    Miyamoto, Yuho
    Ishii, Noriko
    Hasegawa, Kunihiro
    Yuri, Yukihisa
    Takata, Ryo
    Yoh, Kazunori
    Ishii, Akio
    Nakano, Chikage
    Sakai, Yoshiyuki
    Takashima, Tomoyuki
    Ikeda, Naoto
    Nishimura, Takashi
    Iwata, Yoshinori
    Nishikawa, Hiroki
    Iijima, Hiroko
    Nishiguchi, Shuhei
    HEPATOLOGY, 2016, 64 : 306A - 307A
  • [47] Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
    Del Campo, Jose A.
    Gallego-Duran, Rocio
    Gallego, Paloma
    Grande, Lourdes
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (03)
  • [48] Clinical Utility of a Noninvasive Metabolic Approach in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in Type 2 Diabetes
    Bellido, Virginia
    Martinez-Arranz, Ibon
    Goicolea, Ignacio
    Amor, Antonio J.
    Pi, Javier
    Perez, Antonio
    Espiga, Javier
    Montalban, Coral
    Mayo, Rebeca
    Gaztambide, Sonia
    DIABETES, 2020, 69
  • [49] Nonalcoholic Fatty Liver disease (NAFLD)
    Zeuzem, S.
    Trautwein, C.
    GASTROENTEROLOGE, 2020, 15 (02): : 77 - 77
  • [50] Fatty acid levels in nonalcoholic steatohepatitis (NASH) and fatty liver.
    Lau, Y
    Hatch, G
    Minuk, GY
    HEPATOLOGY, 1999, 30 (04) : 546A - 546A
12345